» Articles » PMID: 23029035

A Simplified Approach for the Molecular Classification of Glioblastomas

Overview
Journal PLoS One
Date 2012 Oct 3
PMID 23029035
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Glioblastoma (GBM) is the most common malignant primary brain tumors in adults and exhibit striking aggressiveness. Although GBM constitute a single histological entity, they exhibit considerable variability in biological behavior, resulting in significant differences in terms of prognosis and response to treatment. In an attempt to better understand the biology of GBM, many groups have performed high-scale profiling studies based on gene or protein expression. These studies have revealed the existence of several GBM subtypes. Although there remains to be a clear consensus, two to four major subtypes have been identified. Interestingly, these different subtypes are associated with both differential prognoses and responses to therapy. In the present study, we investigated an alternative immunohistochemistry (IHC)-based approach to achieve a molecular classification for GBM. For this purpose, a cohort of 100 surgical GBM samples was retrospectively evaluated by immunohistochemical analysis of EGFR, PDGFRA and p53. The quantitative analysis of these immunostainings allowed us to identify the following two GBM subtypes: the "Classical-like" (CL) subtype, characterized by EGFR-positive and p53- and PDGFRA-negative staining and the "Proneural-like" (PNL) subtype, characterized by p53- and/or PDGFRA-positive staining. This classification represents an independent prognostic factor in terms of overall survival compared to age, extent of resection and adjuvant treatment, with a significantly longer survival associated with the PNL subtype. Moreover, these two GBM subtypes exhibited different responses to chemotherapy. The addition of temozolomide to conventional radiotherapy significantly improved the survival of patients belonging to the CL subtype, but it did not affect the survival of patients belonging to the PNL subtype. We have thus shown that it is possible to differentiate between different clinically relevant subtypes of GBM by using IHC-based profiling, a method that is advantageous in its ease of daily implementation and in large-scale clinical application.

Citing Articles

Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition.

Xu C, Hou P, Li X, Xiao M, Zhang Z, Li Z Cancer Biol Med. 2024; 21(5).

PMID: 38712813 PMC: 11131044. DOI: 10.20892/j.issn.2095-3941.2023.0510.


Molecular diversity in isocitrate dehydrogenase-wild-type glioblastoma.

Fares J, Wan Y, Mair R, Price S Brain Commun. 2024; 6(2):fcae108.

PMID: 38646145 PMC: 11032202. DOI: 10.1093/braincomms/fcae108.


The clinical value of proneural, classical and mesenchymal protein signatures in WHO 2021 adult-type diffuse lower-grade gliomas.

Denes A, Bontell T, Barcheus H, Ferreyra Vega S, Caren H, Lindskog C PLoS One. 2023; 18(5):e0285732.

PMID: 37192181 PMC: 10187920. DOI: 10.1371/journal.pone.0285732.


Immunohistochemically Characterized Intratumoral Heterogeneity Is a Prognostic Marker in Human Glioblastoma.

Liesche-Starnecker F, Mayer K, Kofler F, Baur S, Schmidt-Graf F, Kempter J Cancers (Basel). 2020; 12(10).

PMID: 33066251 PMC: 7602025. DOI: 10.3390/cancers12102964.


Tumour-specific Causal Inference Discovers Distinct Disease Mechanisms Underlying Cancer Subtypes.

Xue Y, Cooper G, Cai C, Lu S, Hu B, Ma X Sci Rep. 2019; 9(1):13225.

PMID: 31519988 PMC: 6744493. DOI: 10.1038/s41598-019-48318-7.


References
1.
Kajdacsy-Balla A, Geynisman J, Macias V, Setty S, Nanaji N, Berman J . Practical aspects of planning, building, and interpreting tissue microarrays: the Cooperative Prostate Cancer Tissue Resource experience. J Mol Histol. 2007; 38(2):113-21. DOI: 10.1007/s10735-006-9054-5. View

2.
McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97(16):1180-4. DOI: 10.1093/jnci/dji237. View

3.
Hatanpaa K, Burma S, Zhao D, Habib A . Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia. 2010; 12(9):675-84. PMC: 2933688. DOI: 10.1593/neo.10688. View

4.
Nikiforova M, Hamilton R . Molecular diagnostics of gliomas. Arch Pathol Lab Med. 2011; 135(5):558-68. DOI: 10.5858/2010-0649-RAIR.1. View

5.
Hegi M, Diserens A, Gorlia T, Hamou M, De Tribolet N, Weller M . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003. DOI: 10.1056/NEJMoa043331. View